Rocket Lab's Neutron Debut Slides to 2027 on Tank-Dome Flaw, and Wall Street Answers With Smaller Targets, Same Conviction
Published on 10/18/2026 at 05:03 | Editorial boerse-global.de
Rocket Lab closed out the trading week on a sour note, with its shares shedding 8.2% on Friday to finish at 45.25 euros. The retreat capped a punishing seven-day stretch that has erased 26% of the stock's value — a slide that traces directly back to a single disclosure filed with the U.S. Securities and Exchange Commission on Wednesday.
That filing reset the clock on Neutron, the company's flagship medium-lift rocket. The maiden flight, previously penciled in for the fourth quarter of 2026, will now slip into 2027 at the earliest. The culprit sits in the factory rather than on the launch pad: manufacturing trouble with the fuel-tank domes on the first stage.
Voids in the dome, and a production line in rework
According to media accounts, Rocket Lab traced the defect to air pockets trapped within the dome structures. The company has since adjusted its production process to prevent a repeat of the flaw. CEO Peter Beck stressed in the SEC filing that the manufacturing difficulties have now been resolved, though the required inspections and rework still demand their pound of flesh — pushing the first flight unavoidably into 2027.
The timing stings. Electron, Rocket Lab's smaller workhorse, already hauls payloads reliably, but Neutron was meant to unlock the lucrative end of the market: heavy contracts and constellation launches. Industry observers note that the delay only tightens an already strained global supply of launch capacity for medium-sized payloads.
Should investors sell immediately? Or is it worth buying Rocket Lab?
Two houses, two haircuts, one message
Equity analysts moved quickly, though their response was more recalibration than retreat. KeyBanc acted on Thursday, cutting its price target to $100 from $135 while keeping its "Overweight" rating. The firm pointed to the revised Neutron schedule but also flagged sector-wide valuation discounts across high-growth space names.
Citizens followed on Friday, trimming its target to $90 from $130 and maintaining a "Market Outperform" rating. Its rationale centered on the shifted timeline for monetizing rocket launches across the next two years.
Neither firm abandoned ship. Both stressed that demand for dependable launch providers remains robust, even as the new rocket's revenue contribution drifts further into the future. The underlying technology and business model, in their view, are intact — the road to commercial maturity is simply steeper and longer than previously assumed.
A sector that no longer forgives lost time
The sell-off had already begun before Friday's bell. Reuters reported that selling kicked in during after-hours trading immediately after Wednesday's announcement, and the pressure carried through to the end of the week. The episode lands in a sector shifting from experimental pioneering toward industrial-scale serial production — a transition in which investors are growing steadily less tolerant of schedule slippage.
Rocket Lab at a turning point? This analysis reveals what investors need to know now.
Friday's close leaves the stock 66% below its 52-week high, a gap that speaks to how thoroughly the euphoria has drained out of the name. What remains is the hard reality of rocket manufacturing, where even a minor deviation in materials testing can cost millions.
For shareholders, the question now is how fast the production overhaul takes hold. Should Rocket Lab stabilize the revised timeline without further incidents, that could lay the groundwork for calmer trading. The year 2027 looms as the decisive test — only when Neutron actually lifts off will it become clear whether this setback was a temporary dent or a lasting drag on the company's valuation.
Ad
Rocket Lab Stock: New Analysis - 18 October
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
